PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake by Wolf, Markus et al.
 PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits 
efficient cellular uptake 
Markus Wolfa*, Ulrike Bauder-Wüsta and Rüdiger Pipkornb  
 
a
 Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-
69120 Heidelberg, Germany. 
b
 Peptide Synthesis Facility, German Cancer Research Center (DKFZ), TP3 Im Neuenheimer Feld 580, D-69120 
Heidelberg, Germany. 
 
Abstract. The majority of magnetic resonance contrast agents are restricted to the extracellular domains. For  the development of novel, 
intracellular magnetic resonance contrast agents, we have designed Gd-DOTA derivatives comprising  PreS2-TML peptide or 
ethylguanidinium as carrier  moiety. Initial in vitro cell uptake studies with Jurkat cells revealed efficient contrast agent uptake for 
imaging purposes, in the range of 0.04 fmol/cell (PreS2-TML peptide) to 0.2 fmol/cell (ethylguanidinium) following 2 h incubations at 
100 µM. 
To enhance magnetic resonance imaging (MRI) contrast 
between different tissues or between specific tissue 
compartments, a variety of intra- or extravascular 
paramagnetic contrast agents are available, e.g., the 
gadolinium(III) chelation complex [Gd(DTPA)(H2O)]2– 
(commercial name: Magnevist®; generic name: 
gadopentetate dimeglumine; DTPA = 
diethylenetriamine-N,N,N’,N’’,N’’-pentaacetic acid) or 
[Gd(DO3A-butrol)(H2O)] (Gadovist® or gadobutrol; 
DO3A-butrol = 1,4,7-tris(carboxymethyl)-10-(1,2,4-
trihydroxy-but-3-yl)-1,4,7,10-tetraazacyclododecane).1 
A principal barrier to the development of MRI contrast 
agents for investigating biological questions is the 
delivery of agents across cellular membranes. The 
majority of MRI contrast agents are restricted to the 
extracellular domains, and there are few examples of 
membrane permeable MR contrast agents reported in 
the literature.2-7 Recently, we have reported about 
polyamine-based MRI contrast agents with faciliated 
intracellular tumor uptake.8 To achieve a detectable 
contrast enhancement via T1-weighted MRI, on the 
order of 107 - 108 Gd(III) complexes (0.017 - 0.17 fmol) 
per cell need to be internalized. 
Our present research is focussing on the development of 
novel intracellular MRI contrast agents.  
It has been reported that an amphipatic alpha-helix 
between the amino acids 41 and 52 of the PreS2-domain 
of hepatitis-B virus surface antigens mediates cell 
permeability and per se can act as a shuttle for peptides 
and functional proteins.9 Membrane translocation 
occurs in an energy-independent manner.9 Nucleic acids 
with guanidinium modification exhibit efficient cellular 
uptake.10 
 
We propose that conjugation of the PreS2-TML peptide 
or a guanidinium group to Gd-DOTA mediates efficient 
uptake into mammalian cells. The chemical structure of 
the conjugates is outlined in figure1. 
 
The DOTA-ethylguanidinium conjugate was obtained 
by condensation of DOTA-tris(tert. butylester) and 
N,N´-Bis-Boc-protected ehylguanidin in the presence of 
the coupling reagent reagent HATU (O-(7-Azabenzo-
triazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluoro-
phosphate). The protecting groups were cleaved with 
trifluoracetic acid (TFA)/H2O/triisopropylsilane 
(95:2.5:2.5). Reversed-phase HPLC purification of the 
crude product yielded the pure conjugate. 
 
DOTA-PreS2-TML was synthesized automatically on 
Rink amide resin, according to the Merrifield strategy. 
9-Fluorenylmethoxycarbonyl (Fmoc) amino acids were 
coupled in a stepwise manner to the corresponding 
resin.11  2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) in N-
methylpyrrolidone (NMP) was used as coupling agent. 
Fmoc groups were removed using 20% 
piperidine/NMP. The compounds were cleaved from the 
resin with trifluoracetic acid 
(TFA)/H2O/triisopropylsilane (95:2.5:2.5). Reversed-
phase HPLC purification of the crude products yielded 
the pure ligand which was characterized by analytical 
 reversed-phase HPLC and ion-spray mass spectrometry 
(see table 1) to reveal  identity and purity. 
 
 
 
Figure 1: Chemical structure of the ligands. 
 
To a solution of the free ligand in water (16–32 mM) 
was added gadolinium(III)acetate (1.3 equiv.). The 
reaction mixture was heated to 80°C and stirred for 3 hr. 
The reaction mixture was then cooled to ambient 
temperature, and the pH was adjusted to 11 with 
aqueous ammonium hydroxide. The mixture was 
filtered through a 0.2 µm syringe filter, and freeze dried 
to yield a white solid. 
Compds Chemical formula/ 
amino acid 
sequence 
[M+H]+ 
DOTA-ethylguanidin C19H36N8O7 489.01 
Gd-complex of 
DOTA-
ethylguanidin 
C19H33N8O7Gd 644.4 
DOTA-PreS2-TML PLSSIFSRIGDPGGK(DOTA)G-NH2 1973.52 
Gd-complex of 
DOTA-PreS2-TML C86H138N25O28Gd 2127.01 
Table 1. Chemical formulas and mass spectometry data . 
 
Jurkat cells were  obtained from the German Cancer 
Research Center (DKFZ, Heidelberg) tumor bank and 
grown at 37 °C as stock cultures in RPMI 1640 
supplemented with 10% fetal calf serum and 1% 
glutamine as standard medium under a 5% CO2 
atmosphere (all components: Pan Biotech GmbH, 
Aidenbach, Germany). For contrast agent uptake studies 
107 cells were incubated for 2 h  with medium 
containing 0, 10, 25, 50 or 100 µM of the selected 
gadolinium complex. Afterwards the medium was 
removed, the cells were washed twice, resuspended in 
culture medium and counted. The gadolinium content of 
the cells was determined by ICP-MS. Samples 
containing 3 × 106 harvested cells were digested with 
50% concentrated HNO3 (Superselect; Merck, 
Darmstadt, Germany) under microwave heating with a 
Mars 5 apparatus (CEM GmbH, Kamp-Lintfort, 
Germany). To each sample 100 µL of an aqueous 
solution of rhodium chloride (1 µg/mL) were added so 
that Rh-103 could be used as an internal quantification 
standard. Gd-160 measurements were performed with 
the ICP-MS instrument mentioned above. The 
gadolinium concentrations were determined using 
standard curves created prior to cell analyses.  
The uptake of the complexes Gd-1 and Gd-2 after 2-h 
incubation was concentration dependent (Figure 1) and 
reached values in the range 0.04 - 0.02 fmol/cell for the 
100 µM incubation.  
Figure 2: Intracellular uptake of the gadolinium complexes into 
Jurkat cells following 2 h incubations at 37°C. 
The data presented here support the further evaluation 
of these complexes as contrats agents in magnetic 
resonance imaging. 
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